Table 2.
Prevalence of autoantibodies in patients with LN
| Antibodies | NS (n = 214) | Non-NS (n = 215) | OR (95% CI) | P |
|---|---|---|---|---|
| ANA | 206 (96.26) | 204 (94.88) | 1.388 (0.5471-3.524) | 0.6400 |
| Anti-mitochondria | 25 (11.68) | 16 (7.44) | 1.645 (0.8516-3.178) | 0.1430 |
| Anti-ribosome | 47 (21.96) | 63 (29.30) | 0.679 (0.4386-1.051) | 0.0971 |
| Anti-histone | 128 (59.81) | 85 (39.53) | 2.276 (1.5460-3.351) | < 0.0001 |
| Anti-nucleosome | 144 (67.29) | 93 (43.26) | 2.699(1.822-3.998) | < 0.0001 |
| Anti-dsDNA | 158 (73.83) | 107 (49.77) | 2.848 (1.898-4.272) | < 0.0001 |
| Anti-PNCA | 7(3.27) | 4 (1.86) | 1.784 (0.5143-6.187) | 0.3808 |
| Anti-centromere | 5 (2.34) | 5 (2.33) | 1.005 (0.2866-3.523) | 1.0000 |
| Anti-Jo1 | 0 | 0 | undefined | undefined |
| Anti-PM-Scl | 3 (1.40) | 1 (0.47) | 3.043 (0.3138-29.50) | 0.3721 |
| Anti-Scl70 | 4 (1.87) | 7 (3.26) | 0.566 (0.1632-1.963) | 0.5435 |
| Anti-SSB | 37 (17.29) | 36 (16.74) | 1.039 (0.6280-1.720) | 0.8984 |
| Anti-Ro52 | 103 (48.13) | 102 (47.44) | 1.028 (0.7037-1.502) | 0.9231 |
| Anti-SSA | 129 (60.28) | 124 (57.67) | 1.114 (0.7578-1.637) | 0.6239 |
| Anti-Sm | 49 (22.90) | 49 (22.79) | 1.006 (0.6409-1.579) | 1.0000 |
| Anti-RNP | 63 (29.44) | 80 (37.21) | 0.704 (0.4702-1.054) | 0.1013 |
Values are shown as numbers (%)
LN – lupus nephritis; NS – nephrotic syndrome; OR – odds ratio; ANA – antinuclear antibody; anti-dsDNA – anti-double-stranded DNA antibody; anti-PNCA – anti-proliferative cell nuclear antigen; anti-Sm – anti-Smith antibody; anti-SSA – anti-Sjögren's syndrome antigen A; anti-SSB – anti-Sjögren's syndrome antigen B; anti-RNP – anti-ribonucleoprotein; anti-RibP – anti-ribosomal P protein antibody Prevalence of three antibodies tested was significantly increased in LN patients with nephrotic syndrome as compared to patients without nephrotic syndrome p < 0.05 indicates a difference; p < 0.01 indicates a significant difference.